PET-DOPA Metabolic Detection and Characterization of Untreated Brain Metastases of Bronchial, Breast and Melanoma Cancer - DOPACER

INSTITUT DE CANCEROLOGIE DE L'OUEST0 个研究点目标入组 52 人开始时间: 2021年5月10日最近更新: 2024年7月8日

适应症

试验速览

暂无简介。

•1) Histologically proven primary cancer (non-small cell lung, breast or melanoma)
•2) Presence of brain metastasis(s) visualized on MRI, with at least 1 measuring more than 5 mm
•3) Age = 18 years
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 26
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range 26

•1) History of cerebral irradiation
•2) Previous brain surgery for brain metastasis or glial tumor
•3) Systemic therapy (chemotherapy, targeted therapy, immunotherapy) modified in the 6 weeks preceding the PET-DOPA scan,
•4) New anti-tumor treatment (excluding corticosteroids) started between the discovery of CD and the performance of the PET-DOPA scan
•5) Other concomitant cancer, or history of cancer in the 5 years preceding the patient's inclusion in the protocol other than basal or squamous cell carcinoma
•6) Pregnant, likely to be pregnant or breastfeeding

发起方

INSTITUT DE CANCEROLOGIE DE L'OUEST